Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Colloidal Silver Nanoparticles for Chronic Rhinosinusitis
NCT03243201Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
01
Overview
Phase 1, randomised, double-blind trial of silver nanoparticles in chronic rhinosinusitis (CRS) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Sino-Nasal Outcome Test at 4 weeks. Planned start Jan 2018; status: withdrawn.
02
Drugs
silver nanoparticles
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT03243201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243201.